Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perindopril 2mg/indapamide 0.625mg. Fixed low-dose combination.

K J McClellan1, A Markham

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 3, 1999
PubMed
Summary

Fixed low-dose perindopril and indapamide effectively normalize blood pressure in hypertensive patients. This combination therapy demonstrates sustained efficacy and a favorable tolerability profile, reducing hypokalemia risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large-grain scintillator screens for proton radiography.

The Review of scientific instruments·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Physics-informed machine learning for inorganic scintillator discovery.

The Journal of chemical physics·2018
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Nephrology

Background:

  • International guidelines recommend low-dose drug combinations for hypertension management.
  • Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, and indapamide, a non-thiazide diuretic, are frequently used antihypertensive agents.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a fixed low-dose combination of perindopril 2mg/indapamide 0.625mg in patients with essential and isolated systolic hypertension.
  • To assess the pharmacokinetic interactions between perindopril and indapamide.
  • To investigate the effects of perindopril/indapamide on experimental models of hypertension.

Main Methods:

  • Pharmacokinetic studies in healthy volunteers.
  • Experimental hypertension models to assess organ damage and vascular function.
  • Clinical trial involving elderly patients with essential and isolated systolic hypertension treated with daily oral perindopril 2mg/indapamide 0.625mg for approximately one year.

Main Results:

  • No clinically significant pharmacokinetic interactions were observed between perindopril and indapamide.
  • Perindopril/indapamide demonstrated renoprotective and cardioprotective effects in experimental models.
  • Blood pressure normalization was achieved in 83.6% of patients with essential hypertension and 81.7% with isolated systolic hypertension, with sustained control in 79.8% of patients.
  • The fixed combination exhibited a tolerability profile similar to placebo, with most adverse events being mild to moderate.
  • Coadministration reduced the incidence of hypokalemia compared to indapamide monotherapy.

Conclusions:

  • The fixed low-dose combination of perindopril 2mg/indapamide 0.625mg is an effective and well-tolerated treatment for elderly patients with essential and isolated systolic hypertension.
  • The combination therapy offers sustained blood pressure control and a favorable safety profile, including a reduced risk of hypokalemia.
  • Preclinical data suggest beneficial effects on endothelial function and organ protection.

Related Experiment Videos